| S8077 |
RI-1
|
RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM.
|
-
Cell Rep Med, 2025, 6(8):102284
-
MedComm (2020), 2024, 5(8):e690
-
Cell Death Discov, 2024, 10(1):434
|
|
| S8234 |
RS-1
|
RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.
|
-
Sci Bull (Beijing), 2025, S2095-9273(25)00865-5
-
Funct Integr Genomics, 2025, 25(1):180
-
J Biomed Sci, 2024, 31(1):68
|
|
| E0308New |
RAD51-IN-17
|
RAD51-IN-1, a B02 derivative, functions as a potent RAD51 inhibitor. This compound is applicable for cancer research investigations.
|
|
|
| S9941New |
Emzadirib
|
Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.
|
|
|
| S2871 |
T0070907
|
T0070907 is a potent inhibitor of PPARγ (peroxisome proliferator activator receptor γ ) that induces G2/M arrest and enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. It also acts as an antagonist of PPARγ that suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.
|
-
Nucleic Acids Res, 2025, 53(14)gkaf669
-
Cell Rep Med, 2025, 6(10):102373
-
Apoptosis, 2025, 30(5-6):1391-1409
|
|
| S1244 |
Amuvatinib (MP-470)
|
Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. It suppresses c-MET and c-RET, and is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2.
|
-
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220
-
Hematol Oncol, 2025, 43(5):e70131
-
bioRxiv, 2024, 2023.11.21.568071
|
|